N. Zealand To Ban Avandia As Of April 29 For Added Heart Risks
This article was originally published in PharmAsia News
Executive Summary
New Zealand ordered SB Pharmco's Avandia (rosiglitazone) withdrawn from the market by the end of April because of associated heart risks